EUCTR2018-002364-44-IT进行中（未招募）1 期
MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas - Combination of ibrutinib and rituximab in untreated MZ
IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP0 个研究点目标入组 160 人开始时间: 2021年6月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion, each patient must fulfill all of the following criteria:
- •Chemotherapy and immunotherapy-naïve, symptomatic and in need of treatment patients, with histologically proven CD20-positive MZL, not eligible for local therapy, including:
- •1. EMZL (MALT Lymphoma) patients with MALT- IPI score 1-3 in need of systemic therapy.
- •Either de novo or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site with MALT-international prognostic index (IPI) score 1-2 at the time of study entry.
- •1.1.The following patients with gastric MALT Lymphoma can be entered:
- •a)H. pylori-negative cases, either de novo (non pretreated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).
- •b)H. pylori-positive cases at diagnosis, who either first line antibiotics or further local treatment (surgery or radiotherapy), including patients with:
- •-clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication;
- •-clinical (endoscopic) and histological relapse (without H. pylori re-infection), after a remission patients;
- •-persistent (stable) lymphoma at = 1 year post H. pylori eradication.
- •1.2.Similar consideration may be applied to patients with ocular adnexal lymphoma treated with antibiotics.
- •2. SMZL patients in need of therapy.
- •Either de novo or relapsed following local therapy [including surgery and antiviral therapy for Hepatitis C virus (HCV)]. Patient must have a symptomatic disease requiring treatment and be not eligible for splenectomy or not willing to undergo splenectomy.
- •2.1.Patients with SMZL can be entered if any of the following criteria is present:
- •a)bulky progressive or painful splenomegaly;
- •b)enlarged lymph nodes or involvement of extranodal sites with or without cytopenias, i.e. involvement of =3 nodal sites, each with a diameter of =3 cm. Any nodal tumor mass with a diameter of =7 cm (GELG criteria, as adopted in follicular lymphoma) ;
- •c)one of the following symptomatic/progressive cytopenias:
- •- Hgb < 10 g/dL;
- •- ANC < 1000/µL:
- •- PLT< 80 000/µL whatever the reason (autoimmune or hypersplenism or bone marrow infiltration).
- •2.2.Splenectomised patients with rapidly raising lymphocyte counts, lymphadenopathy or involvement of extranodal sites can be entered.
- •2.3.SMZL with concomitant HCV infection who have not responded to or are relapsed after antiviral therapy can be entered
- •3.NMZL patients in need of therapy
- •Either, de novo presenting with disseminated disease or relapsed after local radiotherapy or following antiviral therapy for HCV. Localized nodal MZL is not eligible.
- •4.Measurable or evaluable disease.
- •5.Ann Arbor II-IV (see Appendix B). Stage I disease may be eligible only if not candidate to local therapy (surgery or radiotherapy).
- •6.Age = 18.
- •7.Life expectancy of at least 1 year.
- •8.ECOG Performance status 0-2 .
- •9.Adequate bone marrow function.
- •10.Adequate kidney function
- •11.For women of childbearing potential only: negative serum pregnancy test done within 7 days prior to study drugs administration or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to the first study drugs administration.
- •12.Fertile male or female patients of childbearing potential and their partners must use higly effective contraception during the study and for at least 12 months after the last dose of subcutaneous rituximab and
排除标准
- •1.Any type of lymphoma other than MZL (including MZL with histologic transformation to high-grade lymphoma).
- •2.Localized (stage IE and IIE) gastric, ocular and cutaneous MALT lymphoma that may benefit from local therapy only (surgery or radiotherapy).
- •3.Known CNS involvement of MZL.
- •4.Any previous systemic treatment with immunotherapy or chemotherapy or with BTK inhibitors.
- •5.Major surgery within 4 weeks prior to registration.
- •6.History of stroke or intracranial bleeding within 6 months.
- •7.Known bleeding diathesis (eg, von Willebrand’s disease) or hemophilia.
- •8.Concurrent use of warfarin of other vitamin K antagonists.
- •9.Concurrent use of strong cytochrome P450 (CYP)3A4/5 inhibitors.
- •10.Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
- •11.International normalized ratio (INR) or prothrombin time (PT) =1.5 ULN. Partial thromboplastin time (PTT) or activated PTT (aPTT) =1.5 ULN unless due to lupus anticoagulant.
- •12.Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.
- •13.Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound of ibrutinib and/or rituximab themselves or to the excipients in their formulation).
- •14.Active HCV or Hepatitis B virus (HBV) infections.
- •14. Positive test results for chronic HBV infection (defined as positive
- •HBsAg serology).
- •15. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is
- •undetectable, provided that they are willing to undergo monthly DNA testing and taking specific antiviral prophylaxis, according to
- •local policy. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination are eligible.
- •16. Positive test results for hepatitis C. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
- •17. HIV infection or immunodeficiency.
- •18. Active, severe infections
- •19.Pregnancy or breastfeeding.
- •20.Clinically significant cardiovascular diseases such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
- •21.Any serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •22.Prior history of malignancies other than MZL within 3 years.
- •23.Current enrolment or participation in another therapeutic clinical trial within 28 days prior to treatment start
研究者
相似试验
进行中（未招募）
1 期
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomasEUCTR2018-002364-44-BEIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP175
招募中
1 期
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomasPreviously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatmentMedDRA version: 20.0Level: PTClassification code: 10076596Term: Marginal zone lymphoma Class: 100000004864CTIS2023-507886-25-00Association International Extranodal Lymphoma Study Group (IELSG)185
招募中
2 期
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas2023-507886-25-00Association International Extranodal Lymphoma Study Group (IELSG)178
进行中（未招募）
1 期
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomasPreviously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatmentMedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002364-44-PTIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP175
招募中
2 期
A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies2024-515119-23-00Transgene142